Avatar Mice Underscore the Role of the T Cell-Dendritic Cell Crosstalk in Ebola Virus Disease and Reveal Mechanisms of Protection in Survivors.
Ebola
Ebola virus
T cells
avatar
dendritic cells
humanized mice
mouse models
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
28 09 2022
28 09 2022
Historique:
pubmed:
9
9
2022
medline:
1
10
2022
entrez:
8
9
2022
Statut:
ppublish
Résumé
Ebola virus disease (EVD) is a complex infectious disease characterized by high inflammation, multiorgan failure, the dysregulation of innate and adaptive immune responses, and coagulation abnormalities. Evidence accumulated over the last 2 decades indicates that, during fatal EVD, the infection of antigen-presenting cells (APC) and the dysregulation of T cell immunity preclude a successful transition between innate and adaptive immunity, which constitutes a key disease checkpoint. In order to better understand the contribution of the APC-T cell crosstalk to EVD pathophysiology, we have developed avatar mice transplanted with human, donor-specific APCs and T cells. Here, we show that the transplantation of T cells and APCs from Ebola virus (EBOV)-naive individuals into avatar mice results in severe disease and death and that this phenotype is dependent on T cell receptor (TCR)-major histocompatibility complex (MCH) recognition. Conversely, avatar mice were rescued from death induced by EBOV infection after the transplantation of both T cells and plasma from EVD survivors. These results strongly suggest that protection from EBOV reinfection requires both cellular and humoral immune memory responses.
Identifiants
pubmed: 36073921
doi: 10.1128/jvi.00574-22
pmc: PMC9517696
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0057422Références
J Neuroimmune Pharmacol. 2011 Mar;6(1):148-57
pubmed: 20532647
Nature. 1999 Oct 14;401(6754):708-12
pubmed: 10537110
Sci Rep. 2017 Mar 03;7:43776
pubmed: 28256637
Cell Host Microbe. 2019 Jan 9;25(1):39-48.e5
pubmed: 30629917
J Virol. 2003 Jul;77(14):7945-56
pubmed: 12829834
Immunity. 2013 Jan 24;38(1):187-97
pubmed: 23260195
Adv Immunol. 2013;120:1-49
pubmed: 24070379
J Immunol. 2010 Jan 1;184(1):327-35
pubmed: 20028660
Blood. 2002 Jul 15;100(2):701-3
pubmed: 12091369
J Immunol. 2003 Mar 15;170(6):2797-801
pubmed: 12626527
Lancet. 2021 Feb 27;397(10276):781
pubmed: 33640050
J Infect Dis. 2018 Nov 22;218(suppl_5):S409-S417
pubmed: 30085162
Nature. 1998 Mar 19;392(6673):245-52
pubmed: 9521319
Curr Top Microbiol Immunol. 2017;411:141-169
pubmed: 28653186
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4719-24
pubmed: 25775592
Cell. 2011 Sep 16;146(6):861-2
pubmed: 21925310
Sci Rep. 2017 Nov 7;7(1):14756
pubmed: 29116224
Curr Opin Virol. 2017 Aug;25:90-96
pubmed: 28810165
Nature. 2018 Oct;562(7726):192
pubmed: 30305752
J Infect Dis. 2016 Oct 15;214(suppl 3):S308-S318
pubmed: 27601621
J Infect Dis. 2011 Nov;204 Suppl 3:S757-60
pubmed: 21987747
Science. 2016 Mar 4;351(6277):1078-83
pubmed: 26912366
Nat Med. 1999 Apr;5(4):423-6
pubmed: 10202932
PLoS Pathog. 2016 May 18;12(5):e1005656
pubmed: 27191716
J Infect Dis. 1999 Feb;179 Suppl 1:S108-14
pubmed: 9988173
Nat Med. 2019 Oct;25(10):1470-1471
pubmed: 31591604
Immunity. 2020 Feb 18;52(2):388-403.e12
pubmed: 32023489
JCI Insight. 2019 Nov 1;4(21):
pubmed: 31550241
Nat Immunol. 2003 Oct;4(10):1009-15
pubmed: 14502286
J Infect Dis. 2018 Nov 22;218(suppl_5):S508-S518
pubmed: 29986035
Am J Pathol. 2003 Dec;163(6):2347-70
pubmed: 14633608
Cell Death Dis. 2016 Mar 31;7:e2164
pubmed: 27031961
Immunol Rev. 2010 Mar;234(1):55-75
pubmed: 20193012
J Virol. 2015 Apr;89(8):4700-4
pubmed: 25673711
Nat Immunol. 2016 Oct;17(10):1226-34
pubmed: 27525369
J Immunol. 2009 Sep 15;183(6):3569-73
pubmed: 19717515
J Virol. 2020 Oct 14;94(21):
pubmed: 32817220
J Virol. 2017 Jul 27;91(16):
pubmed: 28592526
J Infect Dis. 2020 Jan 1;221(1):156-161
pubmed: 31301137
Nature. 2016 May 5;533(7601):100-4
pubmed: 27147028